摘要
目的 比较万拉法辛与阿米替林治疗抑郁症患者疗效及安全性.方法 将64例住院的抑郁症患者随机分为服用万拉法辛组和阿米替林组,均治疗8周,用汉米尔顿抑郁量表（HAMD）、临床疗效总评量表（CGI）和副反应量表（TESS）在治疗前及治疗末第12、4、8周比较两组的疗效和安全性.结果 治疗8周两组均有明显的疗效,两组间比较差异无显著性;治疗8周末以万拉法辛组显著较好,万拉法辛组不良反应发生率远低于阿米替林组.结论 抑郁症患者对万拉法辛安全性好疗效高,不良反应少于阿米替林组.
Objective To evaluate the efficacy and side effects of venlafaxime and clomipramine in the treatment of depression. Method 64 patients with depression were randomly divided into catalpa or mirtazapine group for 8 weeks . The efficacy and side effects were evaluated with Hamilton depression scale （ HAMD）, clinical global impression severity of illness （ CGL - SI） and treatment emergent symptom scale （TESS） . Results After 8 weeks treatments, significant improvement was observed in both groups, but no significant in clomipramine group , however the adverse effects was much less in venlafaxime group than in clomipramine group. Conclusion Venlafaxime has better efficacy and less adverse in the maintenance theatment of depression.
